Silence Therapeutics (SLN) Operating Expenses (2024 - 2026)

Silence Therapeutics has reported Operating Expenses for 3 years, with the latest figure at $16.1 million in Q1 2026.

• Quarterly Operating Expenses rose 13245.45% year-over-year to $16.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $42.8 million (down 15.95% YoY) and the FY2025 annual result came in at $28.5 million, up 250.95% from the prior year.
• Operating Expenses improved to $16.1 million in Q1 2026 per SLN's latest filing, from $4.3 million in the prior quarter.
• Over five years, Operating Expenses peaked at $45.7 million in Q4 2024 and troughed at -$3.9 million in Q2 2024.
• A 3-year average of $10.0 million and a median of $4.3 million in 2025 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2025 and 2026: Operating Expenses sank 90.51% in 2025, then surged 13245.45% in 2026.
• Over 3 years, Operating Expenses stood at $45.7 million in 2024, then tumbled by 90.51% to $4.3 million in 2025, then surged by 272.42% to $16.1 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $16.1 million, $4.3 million, and $18.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.